Biomarkers and Signaling Pathways Implicated in the Pathogenesis of Idiopathic Multicentric Castleman Disease/Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis, Renal Insufficiency, and Organomegaly (TAFRO) Syndrome

Remi Sumiyoshi,Tomohiro Koga,Atsushi Kawakami

DOI: https://doi.org/10.3390/biomedicines12061141

IF: 4.757

2024-05-22

Biomedicines

Abstract:Idiopathic multicentric Castleman disease (iMCD) and TAFRO syndrome present a variety of symptoms thought to be caused by excessive inflammatory cytokines and chemokines, but the underlying mechanisms are unknown. iMCD is broadly classified into two types: iMCD-NOS and iMCD-TAFRO, which have distinct laboratory findings, pathological features, and responses to treatments. It is thought that iMCD-NOS, particularly the IPL type, responds favorably to IL-6 inhibitors due to its IL-6-centric profile. iMCD-TAFRO frequently progresses acutely and seriously, similar to TAFRO syndrome. Elevated levels of cytokines, including IL-1β, TNF-α, IL-10, and IL-23, as well as chemokines like CXCL13 and CXCL-10 (especially in iMCD-TAFRO), SAA, and VEGF, have been linked to the disease's pathology. Recent research has identified key signaling pathways including PI3K/Akt/mTOR and JAK-STAT3, as well as those regulated by type I IFN, as crucial in iMCD-TAFRO. These results suggest that dominant pathways may vary between subtypes. Further research into the peripheral blood and lymph nodes is required to determine the disease spectrum of iMCD-NOS/iMCD-TAFRO/TAFRO syndrome.

biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy

What problem does this paper attempt to address?

The problem that this paper aims to solve is the biomarkers and signaling pathways involved in the pathogenesis of idiopathic multicentric Castleman disease (iMCD) and TAFRO syndrome. Specifically, the article explores the following points:

1. **Disease Classification and Clinical Manifestations**: iMCD is divided into two main types - iMCD - NOS (not otherwise specified) and iMCD - TAFRO (associated with thrombocytopenia, edema, fever, reticular fibrosis, renal insufficiency and organomegaly). There are significant differences in laboratory test results, pathological features and treatment responses between these two types.

2. **The Role of Cytokines/Chemokines**: The paper points out that IL - 6 plays a key role in iMCD - NOS, especially in the IPL (idiopathic plasma cell lymphadenopathy) subtype, while iMCD - TAFRO and TAFRO syndrome show more complex cytokine profiles, including IL - 1β, TNF - α, IL - 10, IL - 23, and chemokines CXCL13 and CXCL - 10, etc.

3. **Research on Signaling Pathways**: The study has found the importance of the PI3K/Akt/mTOR and JAK - STAT3 signaling pathways in iMCD - TAFRO, indicating that these pathways may become potential treatment targets. In addition, the Type I interferon (Type I IFN) signaling pathway is also considered to be involved in the pathological process of iMCD - TAFRO.

4. **The Role of T Cells and Their Related Molecules**: The activation state of T cells, especially CD8+ T cells and CD4+ T cells in iMCD - TAFRO, and the role of the PD - 1 pathway in disease progression are also discussed.

5. **Lack of Definite Diagnostic Markers**: At present, there are no exact biomarkers that can be used to distinguish iMCD - NOS, iMCD - TAFRO and TAFRO syndrome. Therefore, further research is needed to determine the diagnostic markers for these diseases.

In summary, this paper attempts to reveal the complex pathogenesis by analyzing the changes of key cytokines, signaling pathways and immune cells involved in different types of iMCD and TAFRO syndrome, and to provide new directions for future diagnosis and treatment.